High-intensity focused ultrasound for prostate cancer
Customize your policy alerts
Sign up for devoted_health Policy MM.76 alerts
Get alerted when Policy MM.76 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage of high-intensity focused ultrasound (HIFU) therapy for prostate cancer and applies to all Devoted Health plans. HIFU is considered medically necessary for recurrent, localized prostate cancer.
The policy underwent an annual update on September 8, 2025.
Medical Necessity Criteria
Medically Necessary Indication
HIFU is considered medically necessary when used for treatment of recurrent, localized prostate cancer.
The policy states this condition is medically necessary; no additional clinical criteria are specified.
Applicable Codes
| 55880 | Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance |
Coverage Considerations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.